[go: up one dir, main page]

DK3013351T3 - Peptider og peptidmimetika i kombinationanvendelser og behandlinger til cancerpatient-subpopulationer - Google Patents

Peptider og peptidmimetika i kombinationanvendelser og behandlinger til cancerpatient-subpopulationer Download PDF

Info

Publication number
DK3013351T3
DK3013351T3 DK14818523.4T DK14818523T DK3013351T3 DK 3013351 T3 DK3013351 T3 DK 3013351T3 DK 14818523 T DK14818523 T DK 14818523T DK 3013351 T3 DK3013351 T3 DK 3013351T3
Authority
DK
Denmark
Prior art keywords
peptid
mimetics
peptides
treatments
cancer patient
Prior art date
Application number
DK14818523.4T
Other languages
English (en)
Inventor
Takumi Kawabe
Naoki Mine
Naoya Saito
Keiichi Sakakibara
Takuji Sato
Original Assignee
Canbas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52141164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3013351(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Canbas Co Ltd filed Critical Canbas Co Ltd
Application granted granted Critical
Publication of DK3013351T3 publication Critical patent/DK3013351T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK14818523.4T 2013-06-24 2014-06-24 Peptider og peptidmimetika i kombinationanvendelser og behandlinger til cancerpatient-subpopulationer DK3013351T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361838777P 2013-06-24 2013-06-24
PCT/IB2014/001579 WO2014207556A1 (en) 2013-06-24 2014-06-24 Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations

Publications (1)

Publication Number Publication Date
DK3013351T3 true DK3013351T3 (da) 2020-01-27

Family

ID=52141164

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14818523.4T DK3013351T3 (da) 2013-06-24 2014-06-24 Peptider og peptidmimetika i kombinationanvendelser og behandlinger til cancerpatient-subpopulationer

Country Status (27)

Country Link
US (1) US9221872B2 (da)
EP (1) EP3013351B1 (da)
JP (1) JP6401255B2 (da)
KR (1) KR102247493B1 (da)
CN (1) CN105324121A (da)
AU (1) AU2014300713B2 (da)
BR (1) BR112015032542A2 (da)
CA (1) CA2916136C (da)
CL (1) CL2015003704A1 (da)
CY (1) CY1122523T1 (da)
DK (1) DK3013351T3 (da)
ES (1) ES2765300T3 (da)
HR (1) HRP20192264T1 (da)
HU (1) HUE046873T2 (da)
IL (1) IL243266B (da)
LT (1) LT3013351T (da)
MX (1) MX366341B (da)
MY (1) MY182232A (da)
PH (1) PH12015502855B1 (da)
PL (1) PL3013351T3 (da)
PT (1) PT3013351T (da)
RS (1) RS60180B1 (da)
RU (1) RU2732440C2 (da)
SG (1) SG11201510490VA (da)
SI (1) SI3013351T1 (da)
WO (1) WO2014207556A1 (da)
ZA (1) ZA201600089B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
KR102236829B1 (ko) 2013-03-15 2021-04-07 프로타고니스트 테라퓨틱스, 인코포레이티드 헵시딘 유사체 및 이의 용도
KR20170028307A (ko) 2014-05-16 2017-03-13 프로타고니스트 테라퓨틱스, 인코포레이티드 α4β7 인테그린 티오에테르 펩티드 길항제
SG11201700327WA (en) 2014-07-17 2017-02-27 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
EP3200812B8 (en) 2014-10-01 2021-04-28 Protagonist Therapeutics, Inc. Novel alpha4beta7 peptide monomer and dimer antagonists
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US10149887B2 (en) * 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
TWI805542B (zh) * 2015-10-23 2023-06-21 日商坎巴斯有限公司 用於癌症治療之肽及擬肽與t細胞活化劑及/或查核點抑制劑之組合
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2017165676A1 (en) 2016-03-23 2017-09-28 Protagonist Therapeutics, Inc. METHODS FOR SYNTHESIZING α4β7 PEPTIDE ANTAGONISTS
CN116655730A (zh) 2016-06-01 2023-08-29 雅斯娜 用于治疗多种疾病的n-己酸-l-酪氨酸-l-异亮氨酸-(6)-氨基己酰胺的衍生物
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
US11753443B2 (en) 2018-02-08 2023-09-12 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
MX2022000397A (es) 2019-07-10 2022-04-25 Protagonist Therapeutics Inc Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
TW202515892A (zh) 2020-01-15 2025-04-16 美商健生生物科技公司 介白素-23受體之肽抑制劑及其治療發炎性疾病之用途
WO2021146454A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
KR20230110570A (ko) 2020-11-20 2023-07-24 얀센 파마슈티카 엔.브이. 인터류킨-23 수용체의 펩티드 억제제의 조성물
IL310061A (en) 2021-07-14 2024-03-01 Janssen Biotech Inc Peptide inhibitors linked to fatty residues of the interleukin-23 receptor
CN115837069A (zh) * 2021-08-10 2023-03-24 昆明医科大学 一种具有提高免疫力和抗肿瘤以及延长寿命的多肽及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60322845D1 (de) * 2002-01-17 2008-09-25 Takeda Pharmaceutical Peptide und peptidmimetika mit anti-proliferativer aktivität und deren verwendung
EP1556398B1 (en) * 2002-10-31 2009-09-09 Metabasis Therapeutics, Inc. Novel cytarabine monophosphate prodrugs
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
US7479484B2 (en) * 2003-06-25 2009-01-20 Takeda Pharmaceutical Company Limited Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity
WO2009139497A1 (en) * 2008-05-14 2009-11-19 Takeda Pharmaceutical Company Limited Cbp501 -derived agents and methods based thereon for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents

Also Published As

Publication number Publication date
SI3013351T1 (sl) 2020-03-31
ES2765300T3 (es) 2020-06-08
MX366341B (es) 2019-07-05
SG11201510490VA (en) 2016-01-28
RU2016101718A3 (da) 2018-03-01
IL243266A0 (en) 2016-03-31
JP6401255B2 (ja) 2018-10-10
MX2015017609A (es) 2016-04-15
HK1219905A1 (en) 2017-04-21
EP3013351A1 (en) 2016-05-04
WO2014207556A1 (en) 2014-12-31
HRP20192264T1 (hr) 2020-03-06
PL3013351T3 (pl) 2020-05-18
EP3013351A4 (en) 2017-03-01
CL2015003704A1 (es) 2016-07-29
JP2016522245A (ja) 2016-07-28
IL243266B (en) 2019-11-28
AU2014300713A1 (en) 2016-01-21
KR20160021792A (ko) 2016-02-26
RS60180B1 (sr) 2020-06-30
CA2916136A1 (en) 2014-12-31
BR112015032542A2 (pt) 2017-07-25
MY182232A (en) 2021-01-18
PT3013351T (pt) 2020-01-17
ZA201600089B (en) 2020-02-26
HUE046873T2 (hu) 2020-03-30
RU2732440C2 (ru) 2020-09-16
EP3013351B1 (en) 2019-10-30
CA2916136C (en) 2022-10-18
US9221872B2 (en) 2015-12-29
CN105324121A (zh) 2016-02-10
PH12015502855A1 (en) 2016-04-04
RU2016101718A (ru) 2017-07-28
PH12015502855B1 (en) 2022-02-11
NZ715285A (en) 2021-09-24
LT3013351T (lt) 2020-01-10
AU2014300713B2 (en) 2019-02-14
US20150056301A1 (en) 2015-02-26
KR102247493B1 (ko) 2021-04-30
CY1122523T1 (el) 2021-01-27

Similar Documents

Publication Publication Date Title
DK3013351T3 (da) Peptider og peptidmimetika i kombinationanvendelser og behandlinger til cancerpatient-subpopulationer
PL3303632T3 (pl) Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze
DK3686280T3 (da) Carbohydratdegraderende polypeptid og anvendelser deraf
BR302013004536S1 (pt) Configuração aplicada em curativo médico
SI3294770T2 (sl) Terapevtski in diagnostični postopki za raka
DK3058936T3 (da) Peptidsammensætning og anvendelser deraf
BR302013004565S1 (pt) Configuração aplicada em curativo médico
DK2920197T3 (da) Prolinlåste sammenhæftede peptider og anvendelser deraf
BR112015032392A2 (pt) sistemas e métodos de entrega de terapia usando um dispositivo médico ambulatorial
DK3060237T3 (da) Modificeret omprogrammeringsprotein til anvendelse i behandling af cancer
DK2920313T3 (da) Rekombinante adenovira og anvendelse deraf
DK2986304T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.
DK3083616T3 (da) Bicykliske heterocykliske forbindelser og disses anvendelser i terapi
BR302013006822S1 (pt) Configuração aplicada em curativo médico.
PL3542798T3 (pl) Aceklidyna do zastosowania w leczeniu starczowzroczności
IL239920A0 (en) Compositions and methods for treating chronic inflammation and inflammatory diseases
DK3065759T3 (da) Immunosuppressive midler og deres anvendelse i terapi
DK2883954T3 (da) Peptidbibliotek og anvendelse deraf
HRP20182125T1 (hr) Adenovirus koji izražava fas-himeru i korištenje istog u metodama liječenja raka
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf
DK2967330T3 (da) Medicinsk indretning og eksterne indretningskoordineringssystemer og fremgangsmåder
DK3057979T3 (da) Proteiner med diagnostiske og terapeutiske anvendelser
HRP20182041T1 (hr) Pripravci oksprenolola za liječenje raka
IL254228B (en) Cell therapeutic agent for cancer treatment and combination therapy with same
DK3071563T3 (da) Midler mod cancer og fremstilling deraf